TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17607084

Group type: EXPERIMENTAL
Intervention: Postoperative multi-factorial intervention program
Number of subjects: 199
Study: 16110227

Group type: EXPERIMENTAL
Intervention: In-patient treatment (IP)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Day hospital treatment
Number of subjects: 109
Study: 12390318

Group type: EXPERIMENTAL
Intervention: Ribavirin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control
Number of subjects: 18
Study: 9932970

Group type: EXPERIMENTAL
Intervention: Intracarotid amobarbital test (IAT)
Number of subjects: 23
Study: 7539966

Group type: EXPERIMENTAL
Intervention: rhG‐CSF
Number of subjects: 20

Group type: COMPARATOR
Intervention: Chemotherapy alone (no G‐CSF)
Number of subjects: 20
Study: 2185673

Group type: EXPERIMENTAL
Intervention: Sublingual captopril 12.5 mg
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sublingual captopril 25 mg
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sublingual captopril (both doses)
Number of subjects: 40
Study: 647173

Group type: EXPERIMENTAL
Intervention: Hypnotic induction procedure
Number of subjects: 40

Group type: COMPARATOR
Intervention: Motivational instructions
Number of subjects: 40
Study: 31648336

Group type: EXPERIMENTAL
Intervention: Lestaurtinib
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Flt3L measurement combined with minimal residual disease (MRD) status
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Flt3L measurement
Number of subjects: 140
Study: 28982943

Group type: EXPERIMENTAL
Intervention: Supervised exercise training for 3 months
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 64
Study: 26026461

Group type: EXPERIMENTAL
Intervention: Multiblock copolymers with high block-size polydispersity and lamellar structures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Block-size distribution P(k) for random copolymers
Number of subjects: 0
Study: 23387416

Group type: EXPERIMENTAL
Intervention: IMAAC (600 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate (600 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 20447833

Group type: EXPERIMENTAL
Intervention: Tamoxifen only
Number of subjects: 131

Group type: COMPARATOR
Intervention: Wedge mastectomy only
Number of subjects: 131
Study: 18649152

Group type: EXPERIMENTAL
Intervention: Remote Programming System (RPS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard on-site CI programming
Number of subjects: 24
Study: 17679046

Group type: EXPERIMENTAL
Intervention: Pro/Col
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pro/Cr
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Col/Cr
Number of subjects: 49

Group type: COMPARATOR
Intervention: Pro
Number of subjects: 49
Study: 15096445

Group type: EXPERIMENTAL
Intervention: levobupivacaine 0.5%
Number of subjects: 60

Group type: COMPARATOR
Intervention: ropivacaine 0.5%
Number of subjects: 60
Study: 11793035

Group type: EXPERIMENTAL
Intervention: Dual therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone)
Number of subjects: 249

Group type: COMPARATOR
Intervention: Triple therapy (oral tacrolimus 0.2 mg/kg daily + oral prednisone + oral azathioprine)
Number of subjects: 249
Study: 9551778

Group type: EXPERIMENTAL
Intervention: 3 g dextrose tablets and 15 mg nicotine transdermal patch
Number of subjects: 308

Group type: COMPARATOR
Intervention: dextrose and placebo patch
Number of subjects: 308

Group type: COMPARATOR
Intervention: placebo tablets and nicotine patch
Number of subjects: 308

Group type: COMPARATOR
Intervention: placebo tablets and placebo patch
Number of subjects: 308
Study: 7998359

Group type: EXPERIMENTAL
Intervention: Padma-28 (340 mg dried herbal mixture, 2 tablets twice daily for four months)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 36
Study: 3176957

Group type: EXPERIMENTAL
Intervention: Continuous infusion epidural analgesia (EDA) with bupivacaine throughout delivery (group B)
Number of subjects: 180

Group type: COMPARATOR
Intervention: No infusion analgesia in the second stage of labor (group A)
Number of subjects: 180
Study: 31785179

Group type: EXPERIMENTAL
Intervention: Regular dental attendance
Number of subjects: 3553

Group type: COMPARATOR
Intervention: Inconsistent dental attendance
Number of subjects: 3553
Study: 30380948

Group type: EXPERIMENTAL
Intervention: 0.625 mg conjugated equine estrogens (CEE) plus 100 mg micronized progesterone (MP)
Number of subjects: 123

Group type: COMPARATOR
Intervention: 0.3 mg CEE plus 100 mg MP
Number of subjects: 123

Group type: COMPARATOR
Intervention: 0.625 mg CEE plus 10 mg dydrogesterone
Number of subjects: 123
Study: 27315664

Group type: COMPARATOR
Intervention: Single fraction of 8 Gy
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: 6 fractions of 4 Gy
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Radiation therapy
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: High pain score and intake of opioids
Number of subjects: 1157

Group type: EXPERIMENTAL
Intervention: Poor performance score
Number of subjects: 1157
Study: 25691501

Group type: EXPERIMENTAL
Intervention: Salvia divinorum
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study: 23868890

Group type: EXPERIMENTAL
Intervention: Intervention group (received smoking cessation intervention)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group (received no specific smoking cessation intervention)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 168

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 168
Study: 21138388

Group type: EXPERIMENTAL
Intervention: Intra-articular prolotherapy (dextrose water)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intra-articular steroid injection (triamcinolone acetonide)
Number of subjects: 48
Study: 17888020

Group type: EXPERIMENTAL
Intervention: 12-week combined exercise group (EG, n = 8)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (CG, n = 9)
Number of subjects: 17
Study: 16191133

Group type: EXPERIMENTAL
Intervention: Nicotine replacement plus behavioral treatment
Number of subjects: 383

Group type: COMPARATOR
Intervention: Nicotine replacement alone
Number of subjects: 383
Study: 12826989

Group type: EXPERIMENTAL
Intervention: Triazolam (0.5 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Meprobamate (2,400 mg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Butabarbital (400 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 10586177

Group type: EXPERIMENTAL
Intervention: Indomethacin (0.2 mg/kg)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Ibuprofen (10 mg/kg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Indomethacin
Number of subjects: 17
Study: 8966003

Group type: EXPERIMENTAL
Intervention: Interferon
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Number of subjects: 118

Group type: COMPARATOR
Intervention: Laser alone
Number of subjects: 118
Study: 1670723

Group type: EXPERIMENTAL
Intervention: Remission reinforcement therapy (teniposide, cytarabine, high‐dose methotrexate)
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Four pairs of drugs rotated weekly or every 6 weeks
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Intensified chemotherapy
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: Higher-risk patients received 1800 cGy cranial irradiation after 1 year of remission
Number of subjects: 358
Study: 6343175

Group type: EXPERIMENTAL
Intervention: Cimetidine 400 mg twice daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 30959514

Group type: EXPERIMENTAL
Intervention: GHB (50 mg/kg p.o.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 28826246

Group type: EXPERIMENTAL
Intervention: Full programme (educational lecture + conversation)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Conversation only
Number of subjects: 38
Study: 27128712

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2)) every 14 days for four cycles
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg m(‐2)) and cyclophosphamide (600 mg m(‐2))
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Doxorubicin exposure
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Doxorubicin and NT‐proBNP
Number of subjects: 17
Study: 24888266

Group type: EXPERIMENTAL
Intervention: Open gastric mobilization and right thoracotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric mobilization and right thoracotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Totally minimally invasive surgery (Bristol center only)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient-reported outcomes measures
Number of subjects: 0
Study: 22748455

Group type: EXPERIMENTAL
Intervention: Circadian Rhythm (CR) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuous Sedation (CS) group
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Demand Sedation (DS) group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Daily Interruption (DI) group
Number of subjects: 90
Study: 19694630

Group type: EXPERIMENTAL
Intervention: Venlafaxine monotherapy for 12 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Prior lithium monotherapy
Number of subjects: 17
Study: 17627232

Group type: EXPERIMENTAL
Intervention: Islet cell transplantation (ICT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 21
Study: 18022033

Group type: EXPERIMENTAL
Intervention: Rimonabant 20 mg per day
Number of subjects: 4105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4105
Study: 14499049

Group type: EXPERIMENTAL
Intervention: Routine data collection
Number of subjects: 0
Study: 10745071

Group type: EXPERIMENTAL
Intervention: 15 mg gossypol/day for 12 or 16 weeks, then randomized to either 7.5 or 10 mg/day for 40 weeks
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 7.5 mg/day gossypol
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: 10 mg/day gossypol
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: gossypol treatment
Number of subjects: 151
Study: 9363971

Group type: EXPERIMENTAL
Intervention: Diet 1 (30% fat)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 2 (26% fat)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 3 (22% fat)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 4 (18% fat)
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 1 (30% fat) for CHL
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 2 (26% fat) for CHL
Number of subjects: 444

Group type: EXPERIMENTAL
Intervention: Diet 3 (25% fat) for CHL
Number of subjects: 444
Study: 1529683

Group type: EXPERIMENTAL
Intervention: Autologous blood transfusion using the Solcotrans Orthopaedic device
Number of subjects: 56

Group type: COMPARATOR
Intervention: Homologous blood transfusion (Control)
Number of subjects: 56
Study: 2936546

Group type: EXPERIMENTAL
Intervention: special astringent cream under disposable polyethylene gloves
Number of subjects: 64

Group type: COMPARATOR
Intervention: cotton inner gloves under polyethylene gloves
Number of subjects: 64
Study: 31246926

Group type: EXPERIMENTAL
Intervention: Night optical device (NOD) technology in blackout conditions (BC)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Normal light conditions (LC)
Number of subjects: 6
Study: 29528455

Group type: EXPERIMENTAL
Intervention: Lumbar sympathetic block with 0.25% bupivacaine
Number of subjects: 4

Group type: COMPARATOR
Intervention: Sham needle placement
Number of subjects: 4
Study: 25994357

Group type: EXPERIMENTAL
Intervention: Brief tailored feedback report plus three motivational interviewing‐based calls from trained peer counselors (n=40)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Report only (n=20)
Number of subjects: 60
Study: 24811605

Group type: EXPERIMENTAL
Intervention: CICS (BD Nexiva™)
Number of subjects: 359

Group type: COMPARATOR
Intervention: Conventional catheter
Number of subjects: 359
Study: 23402680

Group type: EXPERIMENTAL
Intervention: BTX plus physical therapy (PT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: BTX only (control group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: BTX plus PT
Number of subjects: 40
Study: 19809408

Group type: EXPERIMENTAL
Intervention: St John's wort (SJW)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 18630536

Group type: EXPERIMENTAL
Intervention: Auricular acupuncture combined with body acupuncture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Medication group (oral administration of Betaloc and Oryzanol)
Number of subjects: 72
Study: 15995098

Group type: EXPERIMENTAL
Intervention: Intensive case-management intervention
Number of subjects: 273

Group type: COMPARATOR
Intervention: Care as usual (control)
Number of subjects: 273
Study: 12374459

Group type: EXPERIMENTAL
Intervention: Thyroxine plus triiodothyronine (T4 + T3)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thyroxine alone (T4)
Number of subjects: 0
Study: 10352048

Group type: EXPERIMENTAL
Intervention: Presence of a female relative as a labor companion
Number of subjects: 109

Group type: COMPARATOR
Intervention: Labor without family members present (Control)
Number of subjects: 109
Study: 7854155

Group type: EXPERIMENTAL
Intervention: Phenylephrine (Phe)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Angiotensin II (Ang II)
Number of subjects: 0
Study: 1748852

Group type: EXPERIMENTAL
Intervention: Iliad training on simulated patient case presentations
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 6417279

Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 164

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 164
Study: 30624279

Group type: EXPERIMENTAL
Intervention: Combined thresholds for patient's age, PaO2/FIO2, plateau pressure, and extrapulmonary organ failure
Number of subjects: 1200
Study: 29273130

Group type: EXPERIMENTAL
Intervention: Birch subcutaneous allergen immunotherapy (AIT) for 24 months
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Birch subcutaneous allergen immunotherapy (AIT)
Number of subjects: 28
Study: 26562368

Group type: EXPERIMENTAL
Intervention: Early HepB (administered within a few hours after birth)
Number of subjects: 182

Group type: COMPARATOR
Intervention: Late HepB (administered after the repeat CRP)
Number of subjects: 182
Study: 24934774

Group type: EXPERIMENTAL
Intervention: 20mg diazepam nasal spray (NS)
Number of subjects: 24

Group type: COMPARATOR
Intervention: 20mg diazepam rectal gel (RG)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Both intranasal and rectal treatments
Number of subjects: 24
Study: 22092485

Group type: COMPARATOR
Intervention: DBBM (deproteinized bovine bone mineral) with collagen membrane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NCHA (nanocrystalline hydroxyapatite) with collagen membrane
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: NCHA
Number of subjects: 12

Group type: COMPARATOR
Intervention: DBBM
Number of subjects: 12

Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 12
Study: 18342858

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided transvaginal needle ovarian drilling (UTND; n = 82)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Laparoscopic electrosurgery ovarian drilling (n = 81)
Number of subjects: 163
Study: 17484865

Group type: EXPERIMENTAL
Intervention: Natalizumab 300 mg
Number of subjects: 509

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 509
Study: 16091056

Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg
Number of subjects: 497

Group type: EXPERIMENTAL
Intervention: Rabeprazole 10 mg
Number of subjects: 497

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 497
Study: 12359605

Group type: EXPERIMENTAL
Intervention: Iodine 125 (125I) brachytherapy
Number of subjects: 996

Group type: COMPARATOR
Intervention: Charged particle radiation (proton or helium ion)
Number of subjects: 996
Study: 9802271

Group type: EXPERIMENTAL
Intervention: Self-supervised treatment
Number of subjects: 216

Group type: COMPARATOR
Intervention: Direct observation (DO) treatment
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Self-supervised treatment (retreatment patients)
Number of subjects: 216

Group type: COMPARATOR
Intervention: Direct observation (DO) treatment (retreatment patients)
Number of subjects: 216
Study: 7805979

Group type: EXPERIMENTAL
Intervention: Manual Vacuum Aspiration (MVA)
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Sharp Curettage
Number of subjects: 1423
Study: 2678426

Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1190414

Group type: EXPERIMENTAL
Intervention: Subcutaneous infiltration of adrenaline in lignocaine for haemostasis
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enflurane anaesthesia without adrenaline
Number of subjects: 200
Study: 31419597

Group type: EXPERIMENTAL
Intervention: Linguistically‐based treatment of passive sentence production and comprehension (N = 14, treatment group)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Natural history group (N = 5, control group)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Treatment group
Number of subjects: 19
Study: 28067610

Group type: EXPERIMENTAL
Intervention: Computer-assisted cognitive rehabilitation (CR) program (Memory Match, 3 weeks, nine sessions)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Control group (no CR program)
Number of subjects: 43
Study: 24373522

Group type: EXPERIMENTAL
Intervention: Expectation-induced placebo (wound gel)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Non-active gel (control group)
Number of subjects: 22
Study: 22914905

Group type: EXPERIMENTAL
Intervention: Cilnidipine (10 mg/day, increased to 20 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amlodipine (2.5 mg/day, increased to 5 mg/day)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 70

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 70
Study: 21781356

Group type: EXPERIMENTAL
Intervention: Standard PN solutions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Non-randomised analyses of neonatal aluminium intake above the median
Number of subjects: 0
Study: 18414860

Group type: EXPERIMENTAL
Intervention: Bipolar radiofrequency (RF)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monopolar radiofrequency (RF)
Number of subjects: 40
Study: 16454838

Group type: EXPERIMENTAL
Intervention: Rifaximin 400 mg b.i.d.
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 14726063

Group type: EXPERIMENTAL
Intervention: Modified parasternal wire closure (subgroup II B, n = 386)
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Conventional sternal closure (subgroup II A, n = 390)
Number of subjects: 1336

Group type: COMPARATOR
Intervention: Standard six wire closure (Group I, n = 560)
Number of subjects: 1336
Study: 16205336

Group type: EXPERIMENTAL
Intervention: Chiropractic care with and without physical modalities
Number of subjects: 681

Group type: COMPARATOR
Intervention: Medical care with and without physical therapy
Number of subjects: 681
Study: 10600916

Group type: EXPERIMENTAL
Intervention: Allopurinol (XO inhibitor)
Number of subjects: 16

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 16
Study: 8545745

Group type: EXPERIMENTAL
Intervention: Hypoxoside (1,200‐3,200 mg standardized Hypoxis plant extract per day divided in 3 doses)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hypoxoside
Number of subjects: 24
Study: 2322638

Group type: EXPERIMENTAL
Intervention: Sustained release capsules of 120 mg administered every 12 h
Number of subjects: 6

Group type: COMPARATOR
Intervention: Regular 60 mg tablets administered every 6 h
Number of subjects: 6
Study: 7437261

Group type: EXPERIMENTAL
Intervention: Antipyrine in patients treated with antiepileptic drugs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: D‐glucaric acid (D‐GA) excretion in patients treated with antiepileptic drugs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lignocaine in patients treated with antiepileptic drugs
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lignocaine clearance correlation in all subjects
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Lignocaine clearance correlation in normal subjects
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Antipyrine clearance correlation in epileptic patients
Number of subjects: 19
Study: 31077258

Group type: EXPERIMENTAL
Intervention: apremilast 30 mg twice daily
Number of subjects: 1493

Group type: EXPERIMENTAL
Intervention: apremilast 20 mg twice daily
Number of subjects: 1493

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1493
Study: 28424063

Group type: EXPERIMENTAL
Intervention: CIPA screening tool for early detection of malnutrition
Number of subjects: 824

Group type: COMPARATOR
Intervention: Usual inpatient clinical care (Control)
Number of subjects: 824
Study: 27348402

Group type: EXPERIMENTAL
Intervention: Breathing a hyperoxic gas mixture with a constant fraction of 60% inhaled oxygen during exercise training
Number of subjects: 88

Group type: COMPARATOR
Intervention: Breathing up to 40% oxygen as required to maintain an oxygen saturation level of at least 88% during exercise training (control group)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: High oxygen delivery during exercise training
Number of subjects: 88
Study: 25191864

Group type: EXPERIMENTAL
Intervention: Antibiotic treatment
Number of subjects: 431

Group type: COMPARATOR
Intervention: Compression therapy
Number of subjects: 431

Group type: COMPARATOR
Intervention: Ulcer duration, size, and healing time
Number of subjects: 431
Study: 22999402

Group type: EXPERIMENTAL
Intervention: Subxiphoid drain (SX group)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Intercostal drain (IC group)
Number of subjects: 36
Study: 19190969

Group type: EXPERIMENTAL
Intervention: Seasoned surgeons
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control surgeons
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12